X

Drug Profile

EXE 346

Alternative Names: EXE-346

Latest Information Update: 30 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ExeGi Pharma
Class Anti-inflammatories; Bacteria
Mechanism of Action Bacteria replacements; Microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pouchitis
New Molecular Entity No

Highest Development Phases

Phase II Pouchitis

Most Recent Events

11 Oct 2023 Phase I/II clinical trial for Pouchitis in USA (parenteral) (NCT05938465)
26 Jan 2023 The US FDA clears its IND application to initiate clinical trial in Pouchitis in USA
26 Jan 2023 ExeGi Pharma plans to initiate clinical trial in Pouchitis in USA in September 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com